tbuckley/cabot-search huggingface dataset:
Pathologic features, clinical outcomes, and treatment patterns of early-stage triple-negative (TN) breast cancer in an Australian population.
Authors: J. Seah, F. J. Chionh, A. Chakrabarti, S. Deb, S. White
Journal: Journal of Clinical Oncology (2010)

e11102 Background: TN breast cancers are associated with young onset, high-risk pathology, distant metastases and poor prognosis. We examined pathological features, treatment and clinical outcomes of patients (pts) with early-stage TN breast cancer in an Australian population. Methods: Data on pt age, histopathology, treatment and survival outcomes was collected from the pathology database and medical records for 86 pts with histologically confirmed early-stage TN breast cancer resected at Austin Hospital and Northern Hospital (January 1, 2001-February 28, 2009). Results: Mean age at diagnosis was 59 years (y) (range 27-98; SD 15.6); 70% pts were ≥ 50 y. Mean tumour size was 27 mm (range 5-70). Disease stage was I in 26%, II in 61% and III in 13%. 85% were BRE grade 3. 89% pts had ductal carcinoma; the remaining were: atypical medullary (6%), adenoid cystic (2%), lobular (1%) and papillary (1%). Lymphovascular invasion and necrosis were present in 31% and 39% of tumors, respectively. 60% (51/85) had wide local excision (WLE) and 40% (34/85) total mastectomy. 80% (69/86) received adjuvant chemotherapy (CT): 54% (37/69) anthracyline- based, 38% (26/69) taxane-based, and 9% (6/69) other CT. Of the 17 pts not given CT, 11 were unfit, 3 declined and 3 not offered. There was a negative association between age at diagnosis and receiving CT (p < 0.001). 74% (64/86) had adjuvant radiotherapy (RT). During a median follow-up of 28.6 months (m) (range 0.3-120; SD 27.6), 24 pts (28%) had any relapse - 11 locoregional, 18 distant (5 both). For any relapse, disease stage: I in 26%, II in 61% and III in 13%. Median times to any, locoregional and distant relapses were 21.8 m, 33.4 m and 18.6 m, respectively. Sites of distant recurrence were (in descending frequency) lung, bone, brain and others. There were 21 (24%) deaths (median time to death 17 m). Median overall and disease-free survival were 87.8 m and 80.5 m. Conclusions: The majority of TN pts were ≥ 50 y. Most tumors were stage II, high grade and of ductal pathology. Most pts had WLE, adjuvant CT (most commonly anthracycline-based) and RT. Distant relapse was earlier and more common than locoregional, most often in the lung. No significant financial relationships to disclose.
Echocardiography monitoring in patients with Hodgkin's and non-Hodgkin's lymphoma: The Tei-Index evaluation.
Authors: A. Fioretti, S. Oliva, F. Giotta, A. Iacobazzi, A. Guarini, G. Colucci
Journal: Journal of Clinical Oncology (2010)

e18563 Background: Anthracyclines are widely employed in lymphoma's chemotherapy and has been shown to induce heart failure. To monitor this toxic damage, echocardiographic parameters of left ventricular (LV) systolic function are usually used. Aim of this study was to evaluate in lymphoma's patients the reliability of echocardiographic data in comparison with a LV systo-diastolic parameter function: the Tei-Index. Methods: Twenty-nine pts (10 males, 19 females, mean age: 49 yrs) suffering from Hodgkin's and non Hodgkin's lymphoma respectively treated with ABVD or R-CHOP at standard dose. We performed a two-dimensional doppler echocardiography before the first and the fourth chemotherapy cycle, calculating in apical 4 chamber view: LV end-diastolic volume (EDV), end- systolic volume (ESV), ejection fraction (EF) and stroke volume (SV). During mitral and aortic pulse doppler flow, we evaluated the Tei-Index, according to the next formula: Tei-Index = (isovolumetric relaxation time + isometric contraction time)/ejection time. Results: We divided the patients in two groups, according to the presence (Tei+, 9 pts) or the absence (Tei-, 20 pts) of a Tei- Index increase (cut off: 0.1). EF did not change in either group (Tei-: 63.35% vs. 62.34% p=.0809; Tei+: 63.02% vs. 64.78% p=0.2638). In Tei- group EDV, ESV and SV increased from the first to the fourth cycle (EDV: 63.23 ml vs. 70.88 ml p=0.0172 ; ESV: 23.55 ml vs. 26.92 ml p=0.0012; SV: +10.78% p=0.0809). In Tei+ group EDV and ESV did not change (EDV: 73.16 ml vs. 68.59 ml p=0.2426; ESV: 27.35 ml vs. 24.34 ml p=0.2177) and we did not observed a significantly reduction of SV (-7.47%; p=0.3666). Conclusions: According to our data, it seems that SV increase in Tei- pts by increasing the LV volumes. This phenomenon could be explained by early “positive” LV remodeling. On the contrary, Tei+ pts seem not able to counterbalance at the same way and SV reduces, in spite of an unchanged EF. We believe that Tei-Index could be a useful parameter to diagnose the compensative ability of the heart muscle to toxic damage by anthracycline, earlier than EF. Nevertheless, we still have to understand if the remodeling phenomenon observed in Tei- pts could lead to a better prognosis during the follow-up. No significant financial relationships to disclose.
Patients With Lymphocytic Myocarditis Have Increased Lymphocytes in the Skeletal Muscle: A New Diagnostic Tool
Authors: Reindert Emmens, Anna-Pia Papageorgiou, Paolo Carai, Stefanie Smit, Sevgi Seven-Deniz, Lawrence Roozendaal, Walter Paulus, Diana Wouters, Sacha Zeerleder, Jean-Luc Murk, Marieke van Ham, Stephane Heymans, Albert van Rossum, Hans Niessen, Paul Krijnen
Journal: Circulation (2013)
Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient–Derived Xenografts and Mesothelin as a Biomarker of Tumor Response
Authors: Jingli Zhang, Swati Khanna, Qun Jiang, Christine Alewine, Markku Miettinen, Ira Pastan, Raffit Hassan
Journal: Clinical Cancer Research (2016)

Purpose: The purpose of this study was to evaluate the antitumor efficacy of the reduced immunogenicity anti-mesothelin immunotoxin RG7787 plus nab-paclitaxel against primary mesothelioma cell lines and tumor xenografts and the utility of mesothelin as a biomarker of tumor response.Experimental Design: Early-passage human malignant mesothelioma cell lines NCI-Meso16, NCI-Meso19, NCI-Meso21, and NCI-Meso29 were evaluated for sensitivity to RG7787 or nab-paclitaxel alone or in combination. In addition, the antitumor activity of RG7787 plus nab-paclitaxel was evaluated using NCI-Meso16, NCI-Meso21, and NCI-Meso29 tumor xenografts in immunodeficient mice. Serum mesothelin was measured at different time points to determine whether its levels correlated with tumor response.Results: All four primary mesothelioma cell lines highly expressed mesothelin with 41 × 103 to 346 × 103 mesothelin sites per cell and were sensitive to RG7787, with IC50 ranging from 0.3 to 10 ng/mL. Except for NCI-Meso19, these cells were also sensitive to nab-paclitaxel, with IC50 of 10 to 25 ng/mL. In vitro, RG7787 plus nab-paclitaxel led to decreased cell viability compared with either agent alone. In NCI-Meso16 tumor xenografts, treatment with RG7787 plus nab-paclitaxel led to sustained complete tumor regressions. Similar antitumor efficacy was observed against NCI-Meso21 and NCI-Meso29 tumor xenografts. In all three tumor xenograft models, changes in human serum mesothelin correlated with response to therapy and were undetectable in mice with complete tumor regression with RG7787 and nab-paclitaxel.Conclusions: RG7787 plus nab-paclitaxel is very active against primary human mesothelioma cells in vitro as well as in vivo, with serum mesothelin levels correlating with tumor response. These results indicate that this combination could be useful for treating patients with mesothelioma. Clin Cancer Res; 23(6); 1564-74. ©2016 AACR.
Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma
Authors: Alejandra Gutiérrez-González, Mónica Martínez-Moreno, Rafael Samaniego, Noemí Arellano-Sánchez, Laura Salinas-Muñoz, Miguel Relloso, Antonio Valeri, Joaquín Martínez-López, Ángel L. Corbí, Andrés Hidalgo, Ángeles García-Pardo, Joaquín Teixidó, Paloma Sánchez-Mateos
Journal: Blood (2016)
Risk factors of bleeding and clinical implications in patients undergoing liver transplantation
Authors: Mohammed Esmat Gamil, Frederik Nevens, Hannah van Malenstein, Marleen Verhaegen, Bruno Desschans, Diethard Monbaliu, Raymond Aerts, Wim Laleman, David Cassiman, Chris Verslype, Werner Van Steenbergen, Jacques Pirenne
Journal: Hepatology (2011)
IL1RAP antibodies block IL-1–induced expansion of candidate CML stem cells and mediate cell killing in xenograft models
Authors: Helena Ågerstam, Nils Hansen, Sofia von Palffy, Carl Sandén, Kristian Reckzeh, Christine Karlsson, Henrik Lilljebjörn, Niklas Landberg, Maria Askmyr, Carl Högberg, Marianne Rissler, Kimmo Porkka, Hans Wadenvik, Satu Mustjoki, Johan Richter, Marcus Järås, Thoas Fioretos
Journal: Blood (2016)

Chronic myeloid leukemia (CML) is currently treated with tyrosine kinase inhibitors, but these do not effectively eliminate the CML stem cells. As a consequence, CML stem cells persist and cause relapse in most patients upon drug discontinuation. Furthermore, no effective therapy exists for the advanced stages of the disease. Interleukin-1 receptor accessory protein (IL1RAP; IL1R3) is a coreceptor of interleukin-1 receptor type 1 and has been found upregulated on CML stem cells. Here, we show that primitive (CD34+CD38-) CML cells, in contrast to corresponding normal cells, express a functional interleukin-1 (IL-1) receptor complex and respond with NF-κB activation and marked proliferation in response to IL-1. IL1RAP antibodies that inhibit IL-1 signaling could block these effects. In vivo administration of IL1RAP antibodies in mice transplanted with chronic and blast phase CML cells resulted in therapeutic effects mediated by murine effector cells. These results provide novel insights into the role of IL1RAP in CML and a strong rationale for the development of an IL1RAP antibody therapy to target residual CML stem cells.
P1-085: Factors affecting diagnostic accuracy of ct-guided transthoracic needle biopsy of lung lesions: results of 660 consecutive procedures
Authors: Adriano M. Priola, Sandro M. Priola, Silvia Novello, Aldo Cataldi, Luca Errico, Giorgio Garofalo, Matteo Giaj Levra, Marina Longo, Enrica Cappelletto, Cesare Fava
Journal: Journal of Thoracic Oncology (2007)
Epstein-Barr viral miRNAs inhibit antiviral CD4+ T cell responses targeting IL-12 and peptide processing
Authors: Takanobu Tagawa, Manuel Albanese, Mickaël Bouvet, Andreas Moosmann, Josef Mautner, Vigo Heissmeyer, Christina Zielinski, Dominik Lutter, Jonathan Hoser, Maximilian Hastreiter, Mitch Hayes, Bill Sugden, Wolfgang Hammerschmidt
Journal: The Journal of Experimental Medicine (2016)

Epstein-Barr virus (EBV) is a tumor virus that establishes lifelong infection in most of humanity, despite eliciting strong and stable virus-specific immune responses. EBV encodes at least 44 miRNAs, most of them with unknown function. Here, we show that multiple EBV miRNAs modulate immune recognition of recently infected primary B cells, EBV's natural target cells. EBV miRNAs collectively and specifically suppress release of proinflammatory cytokines such as IL-12, repress differentiation of naive CD4+ T cells to Th1 cells, interfere with peptide processing and presentation on HLA class II, and thus reduce activation of cytotoxic EBV-specific CD4+ effector T cells and killing of infected B cells. Our findings identify a previously unknown viral strategy of immune evasion. By rapidly expressing multiple miRNAs, which are themselves nonimmunogenic, EBV counteracts recognition by CD4+ T cells and establishes a program of reduced immunogenicity in recently infected B cells, allowing the virus to express viral proteins required for establishment of life-long infection.
Controlling our brains – a case study on the implications of brain-computer interface-triggered deep brain stimulation for essential tremor
Authors: Timothy Brown, Margaret C. Thompson, Jeffrey Herron, Andrew Ko, Howard Chizeck, Sara Goering
Journal: Brain-Computer Interfaces (2016)

Deep brain stimulators (DBS) are a neurotechnological means of treating a variety of movement disorders, including essential tremor (ET). Current stimulation systems apply an electrical current to targets in the brain at a constant rate for as long as they are implanted and activated – treating symptoms but causing uncomfortable side-effects and inefficient power usage. Some users feel estranged or isolated for various reasons. Next-generation DBS systems could use the patient's self-modulated neural signals to trigger stimulation. These brain-computer interface-triggered DBS (BCI-DBS) systems would give the user the ability to moderate side-effects and reduce battery power consumption. It's not yet clear, however, whether neural control will alleviate or exacerbate psychosocial problems. To explore these concerns, we conducted interviews with an ET patient using an experimental BCI-DBS platform. Our interviews offer preliminary insights about what problems ET patients may face while using BCI-DBS.
Recognition for peer review
Authors: Zoë Mullan
Journal: The Lancet Global Health (2016)

In an age when everything from sparrows to toilets has its own international day (March 20 and November 19, respectively, in case you were wondering), it's perhaps no surprise that the scholarly publishing community has got in on the act. This week is Peer Review Week. Organised by representatives from publishers, the Committee on Publication Ethics (COPE), Sense about Science, ORCID (the organisation that provides authors with unique digital identifiers), and others, the week's aim is “celebrating the essential role that peer review plays in maintaining scientific quality”. Quality is particularly essential for a “high impact” journal such as The Lancet Global Health. Readers expect the papers we publish to be novel, robust, definitive, and generalisable—a tall order, of course, and one that needs a great deal of expertise to identify. All articles chosen for peer review are therefore sent to at least four reviewers—three subject or regional experts and one statistician. These experts are selected individually for each paper on the basis of the editor's own knowledge of the researchers active in the field as well as a bespoke literature review. The reviewers we recruit are therefore generally at the top of their field and provide us with an extensive critical appraisal that can go on for several pages. Sometimes they perform a second review of the revised paper. Sometimes they also write Comment pieces to accompany the research article when it is published. In short, our reviewers are an integral part of the journal, and we are taking the opportunity Peer Review Week affords to publicly acknowledge and sincerely thank all those who reviewed for us over the past 12 months (appendix). These reviewers will also receive a small token of appreciation at the end of the year. I am a member of Council of COPE. Peer Review Week is supported by Elsevier, which publishes The Lancet Global Health. Download .pdf (.49 MB) Help with pdf files Supplementary appendix
AML1/RUNX1, One of the Most Common Targets of Aberration in Acute Myeloid Leukemia as a Transcriptional Regulator of Vascular Endothelial Growth Factor (VEGFA).
Authors: Arja ter Elst, Bin Ma, Frank Scherpen, Bart-Jan A.T. Wierenga, Jan Jacob Schuringa, Jenny Douwes, Willem A. Kamps, Evelina S. de Bont
Journal: Blood (2007)
Nilotinib Exerts Direct Effects on Vascular Endothelial Cells and May Act As a Co-Trigger of Atherosclerosis in Patients with Ph+ CML
Authors: Emir Hadzijusufovic, Susanne Herndlhofer, Karl J. Aichberger, Viviane Ghanim, Verena Suppan, Sabine Cerny-Reiterer, Wolfgang R Sperr, Peter Valent
Journal: Blood (2011)
Change in Neighborhood Characteristics and Change in Coronary Artery Calcium
Authors: Jeffrey J. Wing, Ella August, Sara D. Adar, Andrew L. Dannenberg, Anjum Hajat, Brisa N. Sánchez, James H. Stein, Matthew C. Tattersall, Ana V. Diez Roux
Journal: Circulation (2016)

Although some evidence shows that neighborhood deprivation is associated with greater subclinical atherosclerosis, prior studies have not identified what aspects of deprived neighborhoods were driving the association.We investigated whether social and physical neighborhood characteristics are related to the progression of subclinical atherosclerosis in 5950 adult participants of the MESA (Multi-Ethnic Study of Atherosclerosis) during a 12-year follow-up period. We assessed subclinical disease using coronary artery calcium (CAC). Neighborhood features examined included density of recreational facilities, density of healthy food stores, and survey-based measures of availability of healthy foods, walking environment, and social environment. We used econometric fixed-effects models to investigate how change in a given neighborhood exposure is related to simultaneous change in subclinical atherosclerosis.Increases in density of neighborhood healthy food stores were associated with decreases in CAC (mean changes in CAC Agatston units per 1-SD increase in neighborhood exposures, -19.99; 95% confidence interval, -35.21 to -4.78) after adjustment for time-varying demographic confounders and computed tomography scanner type. This association remained similar in magnitude after additional adjustment for time-varying behavioral risk factors and depression. The addition of time-varying biomedical factors attenuated associations with CAC slightly (mean changes in CAC per 1-SD increase in neighborhood exposures, -17.60; 95% confidence interval, -32.71 to -2.49). Changes across time in other neighborhood measures were not significantly associated with within-person change in CAC.Results from this longitudinal study provide suggestive evidence that greater access to neighborhood healthy food resources may slow the development of coronary atherosclerosis in middle-aged and older adults.
A High-Coverage<i>Yersinia pestis</i>Genome from a Sixth-Century Justinianic Plague Victim
Authors: Michal Feldman, Michaela Harbeck, Marcel Keller, Maria A. Spyrou, Andreas Rott, Bernd Trautmann, Holger C. Scholz, Bernd Päffgen, Joris Peters, Michael McCormick, Kirsten Bos, Alexander Herbig, Johannes Krause
Journal: Molecular Biology and Evolution (2016)

The Justinianic Plague, which started in the sixth century and lasted to the mid eighth century, is thought to be the first of three historically documented plague pandemics causing massive casualties. Historical accounts and molecular data suggest the bacterium Yersinia pestis as its etiological agent. Here we present a new high-coverage (17.9-fold) Y. pestis genome obtained from a sixth-century skeleton recovered from a southern German burial site close to Munich. The reconstructed genome enabled the detection of 30 unique substitutions as well as structural differences that have not been previously described. We report indels affecting a lacl family transcription regulator gene as well as nonsynonymous substitutions in the nrdE, fadJ, and pcp genes, that have been suggested as plague virulence determinants or have been shown to be upregulated in different models of plague infection. In addition, we identify 19 false positive substitutions in a previously published lower-coverage Y. pestis genome from another archaeological site of the same time period and geographical region that is otherwise genetically identical to the high-coverage genome sequence reported here, suggesting low-genetic diversity of the plague during the sixth century in rural southern Germany.
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
Authors: F Stephen Hodi, Jason Chesney, Anna C Pavlick, Caroline Robert, Kenneth F Grossmann, David F McDermott, Gerald P Linette, Nicolas Meyer, Jeffrey K Giguere, Sanjiv S Agarwala, Montaser Shaheen, Marc S Ernstoff, David R Minor, April K Salama, Matthew H Taylor, Patrick A Ott, Christine Horak, Paul Gagnier, Joel Jiang, Jedd D Wolchok, Michael A Postow
Journal: The Lancet Oncology (2016)
Kraissl Lines—A Map
Authors: Eric Laurent Maranda, Robert Heifetz, Jacqueline Cortizo, Farhaan Hafeez, Keyvan Nouri
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Proteomics analysis of cardiac extracellular matrix remodeling in a porcine model of ischemia-reperfusion injury
Authors: Javier Barallobre-Barreiro, Athanasios Didangelos, Xiaoke Yin, M. Fernandez-Caggiano, Ignat Drozdov, P. Willeit, N. Domenech, Manuel Mayr
Journal: Cardiovascular Research (2012)
P2-313: First-line Treatment with Carboplatin and Vinorelbine (CV) in Advanced Non-small Cell Lung Cancer (NSCLC) Patients: A Phase II Study.
Authors: Junta Tanaka, Toru Hiura, Kazuhiko Ito, Akira Iwashima, Hiromi Miyao, Hideyuki Kuriyama, Hiroshi Tanaka, Hiroshi Kagamu, Hirohisa Yoshizawa, Fumitake Gejyo
Journal: Journal of Thoracic Oncology (2007)
Establishing a New Zebrafish Model to Study Malignant Transformation in Myeloproliferative Disorders
Authors: Elisa Alghisi, Michele Malagola, Cristina Santoriello, Cristina Skert, Carla Filì, Cesare Bergonzi, Annalisa Peli, Alessandro Turra, Valeria Cancelli, Rossella Ribolla, Federica Cattina, Marina Mione, Domenico Russo
Journal: Blood (2011)
A randomized study in stage III B and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD: an EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial
Authors: R. Somers, P. Carde, M. Henry-Amar, M. Tarayre, José Thomas, A. Van Hagenbeek, M. Monconduit, B.E. De Pauw, W.P.M. Breed, L. Verdonck, J.M.V. Burgers, H. Eghbali, R. Zittoun
Journal: Journal of Clinical Oncology (1994)
US hospitals mark up prices more than 20-fold to maximize revenue, study suggests
Authors: Michael McCarthy
Journal: BMJ (2016)

US hospitals mark up prices on some services by more than 20-fold, strategically using the markups to maximize their revenue, a study has found.1

The researchers analyzed data from the “chargemasters” of more than 2400 hospitals across the country. These records list the prices hospitals set for services before discounts. Chargemaster prices are typically considerably higher than the actual costs to the hospital.

Hospital executives said that chargemaster prices were largely irrelevant to patients because the actual prices paid by customers were steeply discounted in negotiations with both commercial and public payers. However, patients without insurance, …